These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18503992)

  • 1. Therapy of chronic graft-versus-host disease.
    Arora M
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):271-9. PubMed ID: 18503992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
    Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic graft versus host disease of oral mucosa: review of available therapies.
    Imanguli MM; Pavletic SZ; Guadagnini JP; Brahim JS; Atkinson JC
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Feb; 101(2):175-83. PubMed ID: 16448918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management and outcome of chronic graft-versus-host disease.
    Fraser CJ; Scott Baker K
    Br J Haematol; 2007 Jul; 138(2):131-45. PubMed ID: 17593020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis.
    Fante MA; Holler B; Weber D; Angstwurm K; Bergler T; Holler E; Edinger M; Herr W; Wertheimer T; Wolff D
    Ann Hematol; 2020 Sep; 99(9):2181-2190. PubMed ID: 32715339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic graft-versus-host disease: Pathogenesis and clinical management.
    Pérez-Simón JA; Sánchez-Abarca I; Díez-Campelo M; Caballero D; San Miguel J
    Drugs; 2006; 66(8):1041-57. PubMed ID: 16789791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
    Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease.
    Alsuliman T; Magro L; Coiteux V; Gauthier J; Srour M; Lionet A; Beauvais D; Yakoub-Agha I
    Curr Res Transl Med; 2020 Apr; 68(2):71-76. PubMed ID: 31631014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
    Wolff D; Gerbitz A; Ayuk F; Kiani A; Hildebrandt GC; Vogelsang GB; Elad S; Lawitschka A; Socie G; Pavletic SZ; Holler E; Greinix H
    Biol Blood Marrow Transplant; 2010 Dec; 16(12):1611-28. PubMed ID: 20601036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
    Spałek A; Grygoruk-Wiśniowska I; Gruenpeter K; Panz-Klapuch M; Helbig G
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience.
    Sestili S; Eder S; Belhocine R; Dulery R; Battipaglia G; Brissot E; Mediavilla C; Banet A; van de Wyngaert Z; Paviglianiti A; Ledraa T; Bonin A; Mohty M; Malard F
    Cytotherapy; 2020 Aug; 22(8):445-449. PubMed ID: 32434750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
    Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
    Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
    Gonzalez RM; Pidala J
    Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I treat refractory chronic graft-versus-host disease.
    Sarantopoulos S; Cardones AR; Sullivan KM
    Blood; 2019 Mar; 133(11):1191-1200. PubMed ID: 30674472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease.
    Richet C; Huynh A; Dimeglio C; Borel C; Lepage B; Boulinguez S; Marguery MC; Paul C; Bulai Livideanu C
    Dermatology; 2018; 234(1-2):23-30. PubMed ID: 29788024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.
    Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S
    Clin Transplant; 2014 Dec; 28(12):1410-5. PubMed ID: 25287756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lichen sclerosus et atrophicus-like graft-versus-host disease post stem cell transplant.
    Weinberg JL; Rosenbach M; Kim EJ; Kovarik CL
    Dermatol Online J; 2009 Sep; 15(9):4. PubMed ID: 19930991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.